Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rhoifolin
- Development stage
- Preclinical
- Lead developer
- Affiliated Hospital of Guizhou Medical University
- Modality
- Small Molecules
- Administration
- Oral, Topical, Intraperitoneal, Intratumoral
01
Overview
Rhoifolin is a naturally occurring flavone glycoside (flavonoid) that functions as an inhibitor of the ALDH2-PKC delta signaling axis. In the context of chronic myeloid leukemia (CML), rhoifolin has been shown to selectively eliminate therapy-resistant leukemia stem cells (LSCs) by disrupting mitochondrial metabolic plasticity and oxidative phosphorylation. By targeting the ALDH2-PKC delta hub, it promotes mitophagy and increases chemosensitivity, potentially working in synergy with tyrosine kinase inhibitors (TKIs) to eradicate minimal residual disease (MRD) and prevent disease relapse.
- Other names
- apigenin 7-O-neohesperidosideapigenin7-O-neohesperidosideapigenin-7-O-neohesperidoside
02
Targets
ALDH2 (Mitochondrial Aldehyde Dehydrogenase)PRKCD (Protein kinase C delta)
Beyond the preview
Go deeper on rhoifolin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rhoifolin.